这页已由机器翻译。其他页面可能仍然显示为英文。 View in English

空间免疫评分系统预测肝细胞癌的复发

Gengjie Jia ^1,2,3,4, Peiqi He ^1,2,3, Tianli Dai ^1,2,3

¹Department of Hepatobiliary Surgery, Anhui Provincial Clinical Research Center for Hepatobiliary Diseases, Anhui Province Key Laboratory of Hepatopancreatobiliary Surgery, The First Affiliated Hospital of University of Science and Technology of China (USTC), University of Science and Technology of China, Hefei, China.
²Chinese Academy of Sciences Key Laboratory of Innate Immunity and Chronic Disease, Key Laboratory of Immune Response and Immunotherapy, Institute of Immunology, School of Basic Medical Sciences, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, China.
³Clinical Research Hospital of Chinese Academy of Sciences, University of Science and Technology of China, Hefei, China.
⁴Genome Analysis Laboratory of the Ministry of Agriculture and Rural Affairs, Agricultural Genomics Institute at Shenzhen, Chinese Academy of Agricultural Sciences, Shenzhen, China.
⁵Institute of Molecular and Cell Biology (IMCB), Agency for Science Technology and Research (A*STAR), Singapore, Singapore.
⁶Duke-NUS Medical School, Singapore, Singapore.
⁷Hunan Cancer Hospital, The Affiliated Cancer Hospital of Central South University, Changsha, China.
⁸State Key Laboratory of Genetic Engineering and Collaborative Innovation Center for Genetics and Development, School of Life Sciences, Institutes of Biomedical Sciences, Human Phenome Institute, Fudan University, Shanghai, China.
⁹Institute of Molecular and Cell Biology (IMCB), Agency for Science Technology and Research (A*STAR), Singapore, Singapore. yeongps@imcb.a-star.edu.sg.
¹⁰Department of Anatomical Pathology, Singapore General Hospital, Singapore, Singapore. yeongps@imcb.a-star.edu.sg.
¹¹Singapore Immunology Network (SIgN), Agency for Science Technology and Research (A*STAR), Singapore, Singapore. yeongps@imcb.a-star.edu.sg.
¹²Cancer Science Institute, National University of Singapore, Singapore, Singapore. yeongps@imcb.a-star.edu.sg.
¹³Department of Hepatobiliary Surgery, Anhui Provincial Clinical Research Center for Hepatobiliary Diseases, Anhui Province Key Laboratory of Hepatopancreatobiliary Surgery, The First Affiliated Hospital of University of Science and Technology of China (USTC), University of Science and Technology of China, Hefei, China. liulx@ustc.edu.cn.
¹⁴Department of Hepatobiliary Surgery, Anhui Provincial Clinical Research Center for Hepatobiliary Diseases, Anhui Province Key Laboratory of Hepatopancreatobiliary Surgery, The First Affiliated Hospital of University of Science and Technology of China (USTC), University of Science and Technology of China, Hefei, China. charless@ustc.edu.cn.
¹⁵Chinese Academy of Sciences Key Laboratory of Innate Immunity and Chronic Disease, Key Laboratory of Immune Response and Immunotherapy, Institute of Immunology, School of Basic Medical Sciences, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, China. charless@ustc.edu.cn.

⁰Department of Hepatobiliary Surgery, Anhui Provincial Clinical Research Center for Hepatobiliary Diseases, Anhui Province Key Laboratory of Hepatopancreatobiliary Surgery, The First Affiliated Hospital of University of Science and Technology of China (USTC), University of Science and Technology of China, Hefei, China.

Nature +

|

2025年三月13日

在PubMed上查看摘要

概括

一个新的瘤免疫微环境空间 (TIMES) 评分预测肝细胞癌 (HCC) 复发风险. 这一基于空间生物标志物模式的得分,在早期HCC治疗决策中优于目前的系统和辅助工具.

科学领域

癌症学
免疫学
生物标志物发现

背景情况

肝细胞癌 (HCC) 呈现出高的切除后复发率,因此需要改善风险分层.
准确预测复发对于优化患者的治疗结果和医疗资源分配至关重要.

研究的目的

开发和验证一种用于预测手术后HCC复发风险的新工具.
确定与HCC复发相关的免疫细胞和生物标志物的空间模式.

主要方法

在61名HCC患者中分析了自然杀手细胞和5种生物标志物的空间分布 (SPON2,ZFP36L2,ZFP36,VIM,HLA-DRB1).
瘤免疫微环境空间 (TIMES) 评分的开发,使用极端梯度增强和反变量加权.
在五个中心的231名患者中验证TIMES得分.

主要成果

TIMES评分显示出HCC复发的显著预测能力 (危险比率=88.2,P<0.001),优于TNM和BCLC分期系统.
经过验证的模型在预测复发时达到82.2%的准确性和85.7%的特异性.
生物标志物的预测值取决于空间分布,而不是单个表达水平.
在体内研究显示,SPON2可增强NK细胞透和IFNγ分泌.

结论

泰士评分是一个可靠的,公开可访问的工具,用于预测HCC复发风险.
空间生物标记分析为了解和预测瘤行为提供了一种新的方法.
对于早期的HCC患者来说,TIMES有可能为治疗决策提供信息.